ALX Oncology Holdings Inc. Common Stock (ALXO) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with ALXO
Recent news

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO

ALX Oncology Q1 Earnings Call Highlights
ALX Oncology Q1 Earnings Call Highlights
ALXO

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO
Technical indicators
- RSI 14
- 34.09
- MACD 12/26/9
- -0.19
- EMA 9 of MACD
- -0.18
- MACD histogram
- -0.01
- SMA 50
- $1.77
- Price below SMA 50
- EMA 50
- $1.65
- Price below EMA 50
- SMA 200
- $1.83
- Price below SMA 200
- EMA 200
- $1.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO

ALX Oncology Q1 Earnings Call Highlights
ALX Oncology Q1 Earnings Call Highlights
ALXO

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO
About ALX Oncology Holdings Inc. Common Stock
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jason W. Lettmann | CEO & Director | 1977 |
| Mr. Harish Shantharam C.F.A. | Chief Financial Officer | 1981 |
| Ms. Shelly Wong CPA | Senior VP of Finance & Chief Accounting Officer | 1977 |
| Dr. Barbara J. Klencke M.D. | Chief Medical Officer | 1957 |
| Mr. Jeff E. Knight M.P.H. | Chief Development & Operating Officer | 1972 |
| Mr. Michael Listgarten | General Counsel | — |
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development | — |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance | — |
| Ms. Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance | — |
| Ms. Sue Naim | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 34.09
- MACD 12/26/9
- -0.19
- EMA 9 of MACD
- -0.18
- MACD histogram
- -0.01
- SMA 50
- $1.77
- Price below SMA 50
- EMA 50
- $1.65
- Price below EMA 50
- SMA 200
- $1.83
- Price below SMA 200
- EMA 200
- $1.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +25.6 | -5.2 | -14.1 | +12.4 | +15.0 | -5.8 | +0.0 | -29.8 | -3.8 |



